217 related articles for article (PubMed ID: 8818435)
1. Coagulation and fibrinolytic parameters in patients with pulmonary hypertension.
Altman R; Scazziota A; Rouvier J; Gurfinkel E; Favaloro R; Perrone S; Fareed J
Clin Cardiol; 1996 Jul; 19(7):549-54. PubMed ID: 8818435
[TBL] [Abstract][Full Text] [Related]
2. The effects of nebivolol on fibrinolytic parameters in mild and moderate hypertensive patients.
Tarighi B; Kurum T; Demir M; Azcan SN
Can J Cardiol; 2007 Jun; 23(8):651-5. PubMed ID: 17593991
[TBL] [Abstract][Full Text] [Related]
3. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
4. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE
Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
[TBL] [Abstract][Full Text] [Related]
5. Assessment of fibrinolytic activity by measuring the lysis time of a tissue-factor-induced clot: a feasibility evaluation.
Cellai AP; Lami D; Magi A; Liotta AA; Rogolino A; Antonucci E; Bandinelli B; Abbate R; Prisco D
Clin Appl Thromb Hemost; 2010 Jun; 16(3):337-44. PubMed ID: 19117964
[TBL] [Abstract][Full Text] [Related]
6. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI.
Erem C; Nuhoglu I; Kocak M; Yilmaz M; Sipahi ST; Ucuncu O; Ersoz HO
Endocrine; 2008 Jun; 33(3):270-6. PubMed ID: 19016004
[TBL] [Abstract][Full Text] [Related]
7. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology.
Gris JC; Neveu S; Mares P; Biron C; Hedon B; Schved JF
J Lab Clin Med; 1993 Nov; 122(5):606-15. PubMed ID: 8228580
[TBL] [Abstract][Full Text] [Related]
8. Relationship between endothelial function and fibrinolysis in early hypertension.
Tomiyama H; Kimura Y; Mitsuhashi H; Kinouchi T; Yoshida H; Kushiro T; Doba N
Hypertension; 1998 Jan; 31(1 Pt 2):321-7. PubMed ID: 9453323
[TBL] [Abstract][Full Text] [Related]
9. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension.
Huber K; Beckmann R; Frank H; Kneussl M; Mlczoch J; Binder BR
Am J Respir Crit Care Med; 1994 Oct; 150(4):929-33. PubMed ID: 7921465
[TBL] [Abstract][Full Text] [Related]
10. Fibrinolytic parameters, lipid status and lipoprotein(a) in ischemic stroke patients.
Vucković BA; Djerić MJ; Ilić TA; Canak VB; Kojić-Damjanov SLj; Zarkov MG; Cabarkapa VS
Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():12-7. PubMed ID: 20229676
[TBL] [Abstract][Full Text] [Related]
11. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1.
Urano T; Sakakibara K; Rydzewski A; Urano S; Takada Y; Takada A
Thromb Haemost; 1990 Feb; 63(1):82-6. PubMed ID: 2111051
[TBL] [Abstract][Full Text] [Related]
12. Association between uremic toxin-anthranilic acid and fibrinolytic system activity in predialysis patients at different stages of chronic kidney disease.
Kaminski TW; Pawlak K; Karbowska M; Mysliwiec M; Grzegorzewski W; Kuna J; Pawlak D
Int Urol Nephrol; 2018 Jan; 50(1):127-135. PubMed ID: 29058166
[TBL] [Abstract][Full Text] [Related]
13. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients.
Zuo Y; Warnock M; Harbaugh A; Yalavarthi S; Gockman K; Zuo M; Madison JA; Knight JS; Kanthi Y; Lawrence DA
Sci Rep; 2021 Jan; 11(1):1580. PubMed ID: 33452298
[TBL] [Abstract][Full Text] [Related]
14. Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease.
Salat C; Holler E; Reinhardt B; Kolb HJ; Seeber B; Ledderose G; Mittermueller J; Duell T; Wilmanns W; Hiller E
Bone Marrow Transplant; 1994 Nov; 14(5):747-50. PubMed ID: 7889007
[TBL] [Abstract][Full Text] [Related]
15. Impaired fibrinolysis in hypertension and obesity due to high plasminogen activator inhibitor-1 level in plasma.
Urano T; Kojima Y; Takahashi M; Serizawa K; Sakakibara K; Takada Y; Takada A
Jpn J Physiol; 1993; 43(2):221-8. PubMed ID: 8355419
[TBL] [Abstract][Full Text] [Related]
16. Fibrinolytic system in adolescents: response to venous occlusion stress tests.
Monagle P; Chan AK; Albisetti M; Vegh P; Andrew M; Mitchell L
Pediatr Res; 2003 Feb; 53(2):333-7. PubMed ID: 12538795
[TBL] [Abstract][Full Text] [Related]
17. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
Yasui H; Suzuki Y; Sano H; Suda T; Chida K; Dan T; Miyata T; Urano T
Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258
[TBL] [Abstract][Full Text] [Related]
18. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
19. Effect of blood passage through the pulmonary circulation on fibrinolytic parameters.
Kloboves-Prevodnik V; Sabovic M; Keber D
Heart Vessels; 2004 Jan; 19(1):33-7. PubMed ID: 14685753
[TBL] [Abstract][Full Text] [Related]
20. Tissue-type plasminogen activator after venous occlusion in pregnancy and puerperium.
Stegnar M; Zore A; Novak-Antolic Z; Vovk N; Kruithof EK
Thromb Haemost; 1993 Sep; 70(3):486-90. PubMed ID: 8259554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]